WAM
JUNO

Wolverine Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Wolverine Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,227
Closed -$36K – 1415
2016
Q3 		$36K Buy
+1,227
New +$38.2K ﹤0.01% 1089

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wolverine Asset Management's JUNO Position: Q4 2016 in Review

Wolverine Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 1,227 shares — an estimated $36K sold.

Wolverine Asset Management first reported a position in JUNO in Q3 2016 and held it in 1 quarter. The position peaked at $36K in Q3 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

  • Wolverine Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Wolverine Asset Management sold 1,227 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $36K.
  • Wolverine Asset Management first reported a position in Juno Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Wolverine Asset Management's Juno Therapeutics, Inc. position peaked at $36K in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Wolverine Asset Management's 13F filing for Q4 2016, filed 13 Feb 2017.